Instructions and Data Element Definitions Form DOH-2254A
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Closed Mitral Commissurotomy—A Cheap, Reproducible and Successful Way to Treat Mitral Stenosis
149 Editorial Closed mitral commissurotomy—a cheap, reproducible and successful way to treat mitral stenosis Manuel J. Antunes Clinic of Cardiothoracic Surgery, Faculty of Medicine, University of Coimbra, Coimbra, Portugal Correspondence to: Prof. Manuel J. Antunes. Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal. Email: [email protected]. Provenance and Peer Review: This article was commissioned by the Editorial Office, Journal of Thoracic Disease. The article did not undergo external peer review. Comment on: Xu A, Jin J, Li X, et al. Mitral valve restenosis after closed mitral commissurotomy: case discussion. J Thorac Dis 2019;11:3659-71. Submitted Oct 23, 2019. Accepted for publication Nov 29, 2019. doi: 10.21037/jtd.2019.12.118 View this article at: http://dx.doi.org/10.21037/jtd.2019.12.118 In the August issue of the Journal, Xu et al. (1), from Bayley (4,5) and then became widely accepted. Subsequently, China, discuss the case of a patient who had a successful the technique of CMC suffered several modifications, both reoperation for restenosis of the mitral valve performed in the way the mitral valve was accessed and split. Several 30 years after closed mitral commissurotomy (CMC). instruments were created to facilitate the opening of the The specific aspects of this case were most appropriately commissures, culminating with the development of the commented by several experienced surgeons from different Tubbs dilator, which became the standard instrument for parts of the world. I was now invited by the Editor of this the procedure (Figure 1). Journal to write a Comment on this paper and its subject. -
Pericardiocentesis Versus Pericardiotomy for Malignant Pericardial Effusion: a Retrospective Comparison
MALIGNANT PERICARDIAL EFFUSION, Labbé et al. ORIGINAL ARTICLE Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison C. Labbé MD,* L. Tremblay MD,* and Y. Lacasse MD MSc* ABSTRACT Background Treatment of malignant pericardial effusion remains controversial, because no randomized controlled trials have been conducted to determine the best approach, and results of retrospective studies have been inconsistent. The objective of the present study was to compare pericardiocentesis and pericardiotomy with respect to efficacy for preventing recurrence, and to determine, for those two procedures, diagnostic yields, complication rates, and effects on survival. We also aimed to identify clinical and procedural factors that could predict effusion recurrence. Methods We retrospectively assessed 61 patients who underwent a procedure for treatment of a malignant pericardial effusion at the Institut universitaire de cardiologie et de pneumologie de Québec between February 2004 and September 2013. Results Pericardiocentesis was performed in 42 patients, and pericardiotomy, in 19 patients. The effusion recurrence rate was significantly higher in patients treated with pericardiocentesis than with pericardiotomy (31.0% vs. 5.3%, p = 0.046). The diagnostic yield of the procedures was not significantly different (92.9% vs. 86.7%, p = 0.6). The overall rate of complications was similar in the two groups, as was the median overall survival (2.4 months vs. 2.6 months, p = 0.5). In univariate analyses, the procedure type was the only predictor of recurrence that approached statistical significance. Age, sex, type of cancer, presence of effusion at the time of cancer diagnosis, prior chest irradiation, tamponade upon presentation, and total volume of fluid removed did not influence the recurrence rate. -
Pericardial Injury with Cardiac Tamponade from Multiple Stab Injuries of the Trunk: Incidental Release of Cardiac Tamponade
eISSN: 2508-8033 Treatment Progression in Trauma pISSN: 2508-5298 Pericardial Injury With Cardiac Tamponade From Multiple Stab Injuries of the Trunk: Incidental Release of Cardiac Tamponade Pil Young Jung1, Kwan Wook Kim2 1Department of Surgery, Yonsei university Wonju college of medicine, Wonju Severance Christian Hospital 2Trauma center, Department of Thoracic and Cardiovascular Surgery, CHA University, CHA Bundang Medical Center Traumatic hemopericardium with cardiac tamponade is a rare but life-threatening condition. We report the successful treatment of hemopericardium with cardiac tamponade caused by multiple stab injuries of the trunk. (Trauma Image Proced 2019(1):22-24) Key Words: Hemopericardium, Cardiac tamponade CASE tion of the left internal mammary vessels, which was the cause of hemopericardium (Fig. 3.). The epicardium of From a regional local hospital, a 34-year-old man the right ventricle, the greater omentum, and the spleen who had schizophrenia was transferred to our institution were injured; the diaphragmatic injury may have served with multiple stab injuries of the trunk, sustained in a as a pericardial window of injury into the abdomen suicide attempt (Fig. 1.). At admission, the patient’s vital cavity. We performed ligation of the left internal signs were unstable; cardiac arrest occurred, and return mammary vessels, splenectomy, omentectomy, and of spontaneous circulation was achieved after one cycle primary repair of the diaphragm. The patient recovered of cardiopulmonary resuscitation. The extended focused and was discharged without any complication 24 days assessment sonography in trauma revealed positive signs after admission (Fig. 4.). in the pericardium and splenorenal space. Computed tomographic scans taken at the previous hospital showed DISCUSSION hemopericardium and hemoperitoneum (Fig. -
View Pdf Copy of Original Document
Phenotype definition for the Vanderbilt Genome-Electronic Records project Identifying genetics determinants of normal QRS duration (QRSd) Patient population: • Patients with DNA whose first electrocardiogram (ECG) is designated as “normal” and lacking an exclusion criteria. • For this study, case and control are drawn from the same population and analyzed via continuous trait analysis. The only difference will be the QRSd. Hypothetical timeline for a single patient: Notes: • The study ECG is the first normal ECG. • The “Mildly abnormal” ECG cannot be abnormal by presence of heart disease. It can have abnormal rate, be recorded in the presence of Na-channel blocking meds, etc. For instance, a HR >100 is OK but not a bundle branch block. • Y duration = from first entry in the electronic medical record (EMR) until one month following normal ECG • Z duration = most recent clinic visit or problem list (if present) to one week following the normal ECG. Labs values, though, must be +/- 48h from the ECG time Criteria to be included in the analysis: Criteria Source/Method “Normal” ECG must be: • QRSd between 65-120ms ECG calculations • ECG designed as “NORMAL” ECG classification • Heart Rate between 50-100 ECG calculations • ECG Impression must not contain Natural Language Processing (NLP) on evidence of heart disease concepts (see ECG impression. Will exclude all but list below) negated terms (e.g., exclude those with possible, probable, or asserted bundle branch blocks). Should also exclude normalization negations like “LBBB no longer present.” -
Medicare National Coverage Determinations Manual, Part 1
Medicare National Coverage Determinations Manual Chapter 1, Part 1 (Sections 10 – 80.12) Coverage Determinations Table of Contents (Rev. 10838, 06-08-21) Transmittals for Chapter 1, Part 1 Foreword - Purpose for National Coverage Determinations (NCD) Manual 10 - Anesthesia and Pain Management 10.1 - Use of Visual Tests Prior to and General Anesthesia During Cataract Surgery 10.2 - Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post- Operative Pain 10.3 - Inpatient Hospital Pain Rehabilitation Programs 10.4 - Outpatient Hospital Pain Rehabilitation Programs 10.5 - Autogenous Epidural Blood Graft 10.6 - Anesthesia in Cardiac Pacemaker Surgery 20 - Cardiovascular System 20.1 - Vertebral Artery Surgery 20.2 - Extracranial - Intracranial (EC-IC) Arterial Bypass Surgery 20.3 - Thoracic Duct Drainage (TDD) in Renal Transplants 20.4 – Implantable Cardioverter Defibrillators (ICDs) 20.5 - Extracorporeal Immunoadsorption (ECI) Using Protein A Columns 20.6 - Transmyocardial Revascularization (TMR) 20.7 - Percutaneous Transluminal Angioplasty (PTA) (Various Effective Dates Below) 20.8 - Cardiac Pacemakers (Various Effective Dates Below) 20.8.1 - Cardiac Pacemaker Evaluation Services 20.8.1.1 - Transtelephonic Monitoring of Cardiac Pacemakers 20.8.2 - Self-Contained Pacemaker Monitors 20.8.3 – Single Chamber and Dual Chamber Permanent Cardiac Pacemakers 20.8.4 Leadless Pacemakers 20.9 - Artificial Hearts And Related Devices – (Various Effective Dates Below) 20.9.1 - Ventricular Assist Devices (Various Effective Dates Below) 20.10 - Cardiac -
Appendix A: Surgical Procedure Terms and Definitions
Appendix A: Surgical Procedure Terms and Definitions Anomalous Systemic Venous Connection Anomalous Systemic Venous Connection Repair Repair includes a range of surgical approaches, including, among others: ligation of anomalous vessels, reimplantation of anomalous vessels (with or without use of a conduit), or redirection of anomalous systemic venous flow through directly to the pulmonary circulation (bidirectional Glenn to redirect LSVC or RSVC to left or right pulmonary artery, respectively). Aortic Aneurysm Aortic aneurysm repair Aortic aneurysm repair by any technique. Aortic Dissection Aortic Dissection repair Aortic dissection repair by any technique. Aortic Root Replacement Aortic Root Replacement, Bioprosthetic Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) with a bioprosthesis (e.g., porcine) in a conduit, often composite. Aortic Root Replacement, Mechanical Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) with a mechanical prosthesis in a composite conduit. Aortic Root Replacement, Homograft Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) with a homograft Aortic Root Replacement, Valve sparing Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) without replacing the aortic valve (using a tube graft). Aortic Valve Disease Ross Procedure Replacement of the aortic valve with a pulmonary autograft and replacement of the pulmonary valve with a homograft conduit. Konno Procedure (with and without aortic valve replacement) Relief of left ventricular outflow tract obstruction associated with aortic annular hypoplasia, aortic valvar stenosis and/or aortic valvar insufficiency via Konno aortoventriculoplasty. -
Comparison of Isothermic and Cold Cardioplegia in Cardiac Surgery in Salem District
Pon. A. Rajarajan. Comparison of isothermic and cold cardioplegia in cardiac surgery in Salem District. IAIM, 2019; 6(3): 266-271. Original Research Article Comparison of isothermic and cold cardioplegia in cardiac surgery in Salem District Pon. A. Rajarajan* Associate Professor. Department of Cardio-Thoracic Surgery, Government Mohan Kumaramangalam Medical College Hospital, Salem, Tamil Nadu, India *Corresponding author email: [email protected] International Archives of Integrated Medicine, Vol. 6, Issue 3, March, 2019. Copy right © 2019, IAIM, All Rights Reserved. Available online at http://iaimjournal.com/ ISSN: 2394-0026 (P) ISSN: 2394-0034 (O) Received on: 03-03-2019 Accepted on: 09-03-2019 Source of support: Nil Conflict of interest: None declared. How to cite this article: Pon. A. Rajarajan. Comparison of isothermic and cold cardioplegia in cardiac surgery in Salem District. IAIM, 2019; 6(3): 266-271. Abstract Background: Perioperative myocardial damage is one of the most common causes of morbidity and mortality after heart surgery. The improvement of the technique of myocardial preservation has contributed greatly to significant advances in cardiac surgery. However, serious questions remain regarding the use of warm versus cold cardioplegia, blood versus crystalloid cardioplegia, antegrade versus retrograde delivery and intermittent versus continuous perfusion. Cardioplegic solution is the means by which the ischemic myocardium is protected from cell death. This is achieved by reducing myocardial metabolism through a reduction in cardiac workload and by the use of hypothermia. Chemically, the high potassium concentration present in most cardioplegic solutions decreases the membrane resting potential of cardiac cells. The normal resting potential of ventricular myocytes is about -90 mV. -
ICD-9-CM Procedures (FY10)
2 PREFACE This sixth edition of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) is being published by the United States Government in recognition of its responsibility to promulgate this classification throughout the United States for morbidity coding. The International Classification of Diseases, 9th Revision, published by the World Health Organization (WHO) is the foundation of the ICD-9-CM and continues to be the classification employed in cause-of-death coding in the United States. The ICD-9-CM is completely comparable with the ICD-9. The WHO Collaborating Center for Classification of Diseases in North America serves as liaison between the international obligations for comparable classifications and the national health data needs of the United States. The ICD-9-CM is recommended for use in all clinical settings but is required for reporting diagnoses and diseases to all U.S. Public Health Service and the Centers for Medicare & Medicaid Services (formerly the Health Care Financing Administration) programs. Guidance in the use of this classification can be found in the section "Guidance in the Use of ICD-9-CM." ICD-9-CM extensions, interpretations, modifications, addenda, or errata other than those approved by the U.S. Public Health Service and the Centers for Medicare & Medicaid Services are not to be considered official and should not be utilized. Continuous maintenance of the ICD-9- CM is the responsibility of the Federal Government. However, because the ICD-9-CM represents the best in contemporary thinking of clinicians, nosologists, epidemiologists, and statisticians from both public and private sectors, no future modifications will be considered without extensive advice from the appropriate representatives of all major users. -
Icd-9-Cm (2010)
ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular -
Cardiac Surgery
Minimally Invasive Port-Access Cardiac Surgery Lawrence M Prescott, phlp OVLRVlEW OF CARDIAC SURGERY tions, pain and suffering, convalescence and cost, while main- Since heart surgery was pioneered in the mid-1950s. remark- taining the high efficacy of conventional open-chest surgery. able advances have occurred in the surgical treatment of car- One of these approaches, percutaneous transluminal coro- diovascular disease. Coronary artery bypass graft (CAW) pro- nary angioplasty (PTCA) or balloon angioplasty was devel- cedures are the most effective treatment for coronary artery oped as an altemative to coronary artery bypass graft (CABG) disease. This treatment utilizes an artery or vein to bypass the surgery. While less invasive than conventional CAW, a narrowing in a coronary artery and restore blood flow down- major drawback of PTCA is the high frequency of restenosis, stream of the narrowing. For valvular heart disease (VHD), which occurs at rates ranging from 25 percent to 50 percent. the treatment involves either repairing the diseased heart Ultimately, the majority of angioplasty patients undergo valve, most commonly with the implantation of a prosthetic another PTCA procedure or CABG surgery. annul~plastyring, or replacing it with a prosthetic mechanical Another less-invasive altemative to cokentional open-chest or tissue valve. CABG surgery was developed by a $mall number of cardiac sur- All the surgical procedures in conventional heart surgery geons. For this procedure, surgeons have been using off-the-shelf require a highly invasive technique, a stemotomy, that tools to perform minimally invasive CABG surgery on the beat- involves opening the patient's chest to gain access to the ing heart. -
Structured Review of Post-Cardiotomy Extracorporeal Membrane Oxygenation
ACCEPTED MANUSCRIPT Structured review of post-cardiotomy extracorporeal membrane oxygenation: part 2 - Pediatric patients Roberto Lorussoa*, MD, PhD, Giuseppe Maria Raffab*, MD, Mariusz Kowalewskic , MD, Khalid Alenizya, MD, Niels Sluijpersa, MD, Maged Makhoula, MD, Daniel Brodied, MD, Mike McMullane, MD, I-Wen Wangf, MD, Paolo Meanig, MD, Graeme MacLarenh, MD, Heidi Daltoni, MD, Ryan Barbaroj, MD, Xaotong Houk, MD, Nicholas Cavarocchil, MD, Yih-Sharng Chenm, MD, PhD, Ravi Thiagarajann, MD, PhD, Peta Alexandern, MBBS, Bahaaldin Alsoufio, MD, PhD, Christian A. Bermudezp, MD, Ashish S. Shahq, MD, Jonathan Haftr, MD, Lilia Oretos, MD, David A. D’Alessandrot, MD, Udo Boekenu, MD, PhD, and Glenn Whitmanv, MD From the aCardio-Thoracic Surgery Dept., Heart & Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands; bDepartment for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS—ISMETT (Istituto Mediterraneo per I Trapianti e Terapie ad alta specializzazione), Palermo, Italy; cDepartment of Cardiac Surgery, Antoni Jurasz Memorial University Hospital, Bydgoszcz, Poland; dDivision of Pulmonary & Critical Care Medicine, Columbia University, New York, NY; eCardiac Surgery Unit, Seattle Children Hospital, Seattle, Washington; fCardiac Transplantation and Mechanical Circulatory Support Unit, Indiana University School of Medicine, Health Methodist Hospital, Indianapolis, Indiana; gCardiology Dept., Heart & Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands; -
ICD-9-CM Coordination and Maintenance Committee Meeting September 28-29, 2006 Diagnosis Agenda
ICD-9-CM Coordination and Maintenance Committee Meeting September 28-29, 2006 Diagnosis Agenda Welcome and announcements Donna Pickett, MPH, RHIA Co-Chair, ICD-9-CM Coordination and Maintenance Committee ICD-9-CM TIMELINE .................................................................................................... 2 Hearing loss, speech, language, and swallowing disorders ........................................... 8 Kyle C. Dennis, Ph.D., CCC-A, FAAA and Dee Adams Nikjeh,Ph.D., CCC-SLP American Speech-Language-Hearing Association Urinary risks factors for bladder cancer ...................................................................... 13 Louis S. Liou, M.D., Ph.D., Abbott Chronic Total Occlusion of Artery of Extremities....................................................... 15 Matt Selmon, M.D., Cordis Osteonecrosis of jaw ....................................................................................................... 17 Vincent DiFabio,M.D., American Association of Oral and Maxillofacial Surgeons Intraoperative Floppy Iris Syndrome ........................................................................... 18 Priscilla Arnold, M.D., American Society of Cataract and Refractive Surgery Septic embolism............................................................................................................... 19 Parvovirus B19 ................................................................................................................ 21 Avian Influenza (Bird Flu)............................................................................................